气球样变肝细胞识别复杂性:为非酒精性脂肪性肝病人工智能影像定义训练图谱
本研究评估9位国际肝病病理专家对数字化切片中气球样变肝细胞的识别一致性,发现总体观察者间Fleiss kappa仅0.197(95%CI 0.094-0.300),采用≥5细胞阈值后升至0.362(0.258-0.465),而评估气球样变负荷的一致性ICC为0.718(0.511-0.900)。研究生成一致性图谱用于训练人工智能检测气球样变肝细胞,AI与病理学家成对一致性为19-42%,与病理学家之间成对一致性8-75%相当。
要点
- 专家间对气球样变存在与否的总体一致性差(Fleiss kappa 0.197),采用≥5细胞阈值后仍仅为中等(0.362)。
- 气球样变负荷的一致性ICC为0.718,提示对负担的评估一致性高于对存在与否的判断。
- 一致性图谱可用于训练AI辅助技术,以可重复地量化气球样变肝细胞。
核心结论
- 专家肝病病理学家间对气球样变肝细胞识别的显著差异提示气球样变是一连续谱,其存在或完全缺失作为试验终点过于主观而无法明确判定。
- 一致性图谱可用于训练AI辅助技术以可重复地量化气球样变肝细胞,从而标准化疗效评估。
- 该图谱为后续完善病理学家和AI对气球样变分类的工作提供了参考标准。
研究设计与样本
- 对气球样变肝细胞识别进行专项评估,由9位国际公认的专家肝病病理学家在2个独立场合评估数字化切片。
- 每位病理学家独立标记每个气球样变肝细胞,随后提供整体非NASH NAFL/NASH评估。
- 评估观察者间变异并生成气球样变肝细胞「一致性图谱」,用于训练基于二次谐波生成/双光子激发荧光成像的人工智能。
主要发现
- 气球样变存在/缺失的总体观察者间一致性Fleiss kappa统计量为0.197(95%CI 0.094-0.300),采用≥5细胞阈值后升至0.362(95%CI 0.258-0.465)。
- 一致性组内相关系数为0.718(95%CI 0.511-0.900),表明对气球样变负荷呈「中等」一致性。
- 采用≥5/9多数共识识别出133个气球样变细胞用于训练AI气球样变检测,AI与病理学家成对一致性为19-42%,与病理学家之间成对一致性8-75%相当。
- AI在另一独立切片集中量化了气球样变细胞负荷对治疗的反应变化。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Histologically assessed hepatocyte ballooning is a key feature discriminating non-alcoholic steatohepatitis (NASH) from steatosis (NAFL). Reliable identification underpins patient inclusion in clinical trials and serves as a key regulatory-approved surrogate endpoint for drug efficacy. High inter/intra-observer variation in ballooning measured using the NASH CRN semi-quantitative score has been reported yet no actionable solutions have been proposed. METHODS: A focused evaluation of hepatocyte ballooning recognition was conducted. Digitized slides were evaluated by 9 internationally recognized expert liver pathologists on 2 separate occasions: each pathologist independently marked every ballooned hepatocyte and later provided an overall non-NASH NAFL/NASH assessment. Interobserver variation was assessed and a 'concordance atlas' of ballooned hepatocytes generated to train second harmonic generation/two-photon excitation fluorescence imaging-based artificial intelligence (AI). RESULTS: The Fleiss kappa statistic for overall interobserver agreement for presence/absence of ballooning was 0.197 (95% CI 0.094-0.300), rising to 0.362 (0.258-0.465) with a ≥5-cell threshold. However, the intraclass correlation coefficient for consistency was higher (0.718 [0.511-0.900]), indicating 'moderate' agreement on ballooning burden. 133 ballooned cells were identified using a ≥5/9 majority to train AI ballooning detection (AI-pathologist pairwise concordance 19-42%, comparable to inter-pathologist pairwise concordance of between 8-75%). AI quantified change in ballooned cell burden in response to therapy in a separate slide set. CONCLUSIONS: The substantial divergence in hepatocyte ballooning identified amongst expert hepatopathologists suggests that ballooning is a spectrum, too subjective for its presence or complete absence to be unequivocally determined as a trial endpoint. A concordance atlas may be used to train AI assistive technologies to reproducibly quantify ballooned hepatocytes that standardize assessment of therapeutic efficacy. This atlas serves as a reference standard for ongoing work to refine how ballooning is classified by both pathologists and AI. LAY SUMMARY: For the first time, we show that, even amongst expert hepatopathologists, there is poor agreement regarding the number of ballooned hepatocytes seen on the same digitized histology images. This has important implications as the presence of ballooning is needed to establish the diagnosis of non-alcoholic steatohepatitis (NASH), and its unequivocal absence is one of the key requirements to show 'NASH resolution' to support drug efficacy in clinical trials. Artificial intelligence-based approaches may provide a more reliable way to assess the range of injury recorded as "hepatocyte ballooning".
引用
- Brunt EM, Clouston AD, Goodman Z, et al. Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD. J Hepatol. 2022. PMID: 35090960. doi:10.1016/j.jhep.2022.01.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。